Parathyroid Adenoma Detection With Rubidium-82 Imaging (PARAGON)

Matthieu Pelletier-Galarneau, MD MSc

Status: Not yet enrolling

Conditions: Hyperparathyroidism, Primary; Parathyroid Adenomas

Treatments: Other: PET/CT imaging with rubidium-82

Study type: Observational

Funder types: Other

Identifiers

NCT07099404

MP-33-2025-3547

Details and patient eligibility

About

Assess the uptake of rubidium-82 in parathyroid adenomas.

Full description

Parathyroid adenomas demonstrate uptake of rubidium-82 chloride and can be detected with PET imaging.

The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18y
2. Ability to undergo imaging logistics
3. Ability to provide informed consent
4. Biochemical evidence of primary hyperparathyroidism
5. Documented parathyroid adenoma on prior 18F-fluorocholine imaging

Exclusion criteria

1. Normocalcemic primary hyperparathyroidism
2. Breastfeeding or pregnancy
3. Claustrophobia or inability to undergo imaging logistics
4. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study